POSITION
Co-investor
BOARD
None
Amolyt Pharma is a clinical-stage biotechnology company developing life-changing treatments for patients suffering from rare endocrine and related diseases. Amolyt’s lead product candidate is a novel therapy for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of parathyroid hormone (PTH). PTH is key to regulating and maintaining a balance of calcium and phosphorus in the body.
Amolyt’s lead product candidate, eneboparatide (AZP-3601), is a long-acting PTH1 receptor agonist and a potential best-in-class treatment for hypoparathyroidism. To date, it has completed Phase I/II clinical trials in hypoparathyroid patients, with results demonstrating that the drug is well-tolerated and shows promising efficacy in regulating urinary and serum calcium levels within the target range. The company plans to continue development of eneboparatide through Phase III clinical trials and is also developing AZP-3813, a peptide growth hormone receptor antagonist, for the potential treatment of acromegaly.
On January 6, 2023, Amolyt Pharma announced the closing of a €130 million (approx. $138M USD) Series C equity financing. CTI LSF Fund III participated in this round alongside a roster of world-class VC investors including Sofinnova Partners, Intermediate Capital Group, Andera Partners, Novo Holdings, Pontifax, Orbimed, Sectoral Asset Management, Tekla Capital Investment and Bpifrance Investissement.